Conatus Pharmaceuticals Inc
Most Recent
Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April
Of the four analysts covering Enanta Pharmaceuticals, one analyst gave the stock a “buy” rating and three analysts gave it a “hold.”
Which Gilead Sciences Portfolio Could Give a Long-Term Boost
NASH is a chronic disease related to steatosis wherein fat accumulates in the liver and can lead to inflammation, progressive fibrosis, and cirrhosis.
